Garla, Priscila, Sala, Priscila, de Miranda Torrinhas, Raquel Susana Matos, Mendonça Machado, Natasha, Fonseca, Danielle Cristina, Marques da Silva, Mariane, Ravacci, Graziela Rosa, Belarmino, Giliane, Ishida, Robson Kiyoshi, Guarda, Ismael Francisco Mota Siqueira, Hourneaux de Moura, Eduardo Guimarães, Sakai, Paulo, Santo, Marco Aurélio, Guerreiro da Silva, Ismael Dale Cotrim, Pereira, Claudia Cristina Alves, Heymsfield, Steven, Corrêa-Giannella, Maria Lúcia Cardillo, Calder, Philip and Waitzberg, Dan Linetzky (2019) Reduced intestinal FADS1 gene expression and plasma omega-3 fatty acids following Roux-en-Y gastric bypass. Clinical Nutrition, 38 (3), 1280-1288. (doi:10.1016/j.clnu.2018.05.011).
Abstract
Background & aims
Roux-en-Y gastric bypass (RYGB) limits food ingestion and may alter the intestinal expression of genes involved in the endogenous synthesis of polyunsaturated fatty acids (PUFAs). These changes may decrease the systemic availability of bioactive PUFAs after RYGB.
Aim
To study the impact of RYGB on the dietary ingestion and plasma concentration of PUFAs and on the intestinal expression of genes involved in their endogenous biosynthesis in severely obese women with type 2 diabetes.
MethodsBefore, and 3 and 12 months after RYGB, obese women (n = 20) self-reported a seven-day dietary record, answered a food frequency query and provided plasma samples for alpha-linolenic (ALA), eicosapentaenoic (EPA), docosahexaenoic (DHA) and arachidonic (ARA) acid assessment by gas chromatography. Intestinal biopsies(duodenum, jejunum and ileum) were collected through double-balloon endoscopybefore and 3 months after RYGB for gene expression analysis by microarray (Human GeneChip 1.0 ST array) and RT-qPCR validation.
ResultsCompared to the preoperative period, patients had decreased intakes of PUFAs, fish and soybean oil (p < 0.05) and lower plasma concentrations of ALA and EPA (p < 0.001) 3 and 12 months after RYGB. FADS1 gene expression was lower in duodenum (RT-qPCR fold change = −1.620, p < 0.05) and jejunum (RT-qPCR fold change = −1.549, p < 0.05) 3 months following RYGB, compared to before surgery.
ConclusionRYGB decreased PUFA ingestion, plasma ALA and EPA levels, and intestinal expression of FADS1 gene. The latter encodes a key enzyme involved in endogenous biosynthesis of PUFAs. These data suggest that supplementation of omega-3 PUFAs may be required for obese patients undergoing RYGB. Clinical Trial Registry number and website: www.clinicaltrials.gov – NCT01251016; Plataforma Brasil – 19339913.0.0000.0068.
More information
Identifiers
Catalogue record
Export record
Altmetrics
Contributors
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.